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Randomized Optical Coherence Tomography
tudy of Coronary Stent Strut Coverage and
uminal Protrusion With Rapamycin-Eluting Stents
hilip Moore, MD,* Peter Barlis, MD,* Jonathan Spiro, MD,* Gopal Ghimire, MD,*
ichael Roughton, MSC,* Carlo Di Mario, MD,* William Wallis, MD,*
harles Ilsley, MD,* Andrew Mitchell, MD,* Mark Mason, MD,* Rajesh Kharbanda, MD,*
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bjectives We used optical coherence tomography, which has a resolution of 20 m, to analyze
hin layers of neointima in rapamycin-eluting coronary stents.
ackground Lack of neointimal coverage has been implicated in the pathogenesis of drug-eluting
oronary stent thrombosis. Angiography and intracoronary ultrasound lack the resolution to exam-
ne this.
ethods We conducted a randomized trial in patients receiving polymer-coated rapamycin-eluting
tents (Cypher, Cordis, Johnson & Johnson, Miami, Florida) and nonpolymer rapamycin-eluting stents
Yukon, Translumina, Hechingen, Germany) to examine neointimal thickness, stent strut coverage, and
rotrusion at 90 days. Twenty-four patients (n  12 for each group) underwent stent deployment and
nvasive follow-up at 90 days with optical coherence tomography. The primary end point was binary
tent strut coverage. Coprimary end points were neointimal thickness and stent strut luminal protrusion.
esults No patient had angiographic restenosis. For polymer-coated and nonpolymer rapamycin-
luting stents, respectively, mean (SD), neointimal thickness was 77.2 (25.6) m versus 191.2 (86.7)
m (p  0.001). Binary stent strut coverage was 88.3% (11.8) versus 97.2% (6.1) (p  0.030). Binary
tent strut protrusion was 26.5% (17.5) versus 4.8% (8.6) (p  0.001).
onclusions Mean neointimal thickness for the polymer-coated rapamycin-eluting stent was signiﬁ-
antly less than the nonpolymer rapamycin-eluting stent but as a result coverage was not homoge-
ous, with 10% of struts being uncovered. High-resolution imaging allowed development of the con-
ept of the protrusion index, and 25% of struts protruded into the vessel lumen with the polymer-
oated rapamycin-eluting stent compared with 5% with the nonpolymer rapamycin-eluting stent.
hese ﬁndings may have important implications for the risk of stent thrombosis and, therefore, future
tent design. (An optical coherence tomography study to determine stent coverage in polymer coated
ersus bare metal rapamycin eluting stents. ORCA 1, from the Optimal Revascularization of the Coronary
rteries group; ISRCTN42475919) (J Am Coll Cardiol Intv 2009;2:437–44) © 2009 by the American
ollege of Cardiology Foundation
rom the *Royal Brompton & Harefield NHS Trust, Middlesex, United Kingdom; and the †Department of Aeronautics, Imperial
ollege, London, United Kingdom. This trial was supported through an unrestricted educational grant from Translumina,
ermany. Dr. Dalby has received honoraria from Translumina, Germany. Drs. Moore and Barlis contributed equally to this work
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438olymer-coated drug-eluting coronary stents reduce restenosis
nd repeat revascularization (1,2). Lack of endothelial cover-
ge, however, has been reported as the most powerful predictor
f stent thrombosis in post-mortem series (3), which, in turn,
arries a high mortality (4–6). Coronary angiography and
ntravascular ultrasound lack the resolution to assess thin layers
f coverage. In contrast, optical coherence tomography (OCT)
s safe, feasible, has a resolution of 20 m, and has been
orrelated well with histological analysis of neointima making
t suitable for this application (7–9).
ethods
e undertook a randomized study comparing a polymer-
oated rapamycin-eluting stent (Cypher, Cordis, Johnson &
ohnson, Miami, Florida) with a nonpolymer rapamycin-
luting stent (Yukon, Translumina, Hechingen, Germany)
o examine whether 1 device was superior to the other with
egard to the primary and coprimary end points of binary
tent strut coverage, neointimal thickness, and luminal strut
rotrusion. Approximately 200 patients were screened for
rial participation between October 2006 and July 2007, and
1 were randomized and underwent stent deployment as
part of the study. Twenty-four
patients completed the trial with
90-day angiography and OCT.
Relatively slow recruitment and
significant drop out were due in
large part to patient concerns
about the risks and inconve-
nience associated with follow-up
atheterization and, in particular, the fact that OCT was a
elatively new technology. Blocked randomization was car-
ied out by the use of sealed envelopes, with patients per
lock allocated in a 1:1 ratio between the polymer-coated
nd nonpolymer rapamycin-eluting stents. Follow-up used
0-day angiography with quantitative coronary angiography
nd OCT. Inclusion criteria were age 18 to 75 years, stable
ngina pectoris, or acute coronary syndrome pain-free for
4 h. Exclusion criteria were ST-segment elevation myo-
ardial infarction, cardiogenic shock, chronic total occlu-
ion, bifurcation procedure, left ventricular ejection fraction
30%, and renal impairment (serum creatinine 200
mol1). Stent deployment was performed using angiogra-
hy but without intracoronary imaging. Patients received
oading doses of aspirin (300 mg) and clopidogrel (600 mg)
t least 2 h before the index procedure if they were not on
aintenance therapy, followed by planned lifelong aspirin
5 mg daily and clopidogrel 75 mg daily for a minimum of
year. Ninety days was used as the study end point for 2
easons. First, early reports of OCT in a nonrandomized
eries had presented data from 2-month follow-up demon-
trating a large and significant difference between stent strut
bbreviations
nd Acronyms
MS  bare-metal stent(s)
CT  optical coherence
omography
D  three-dimensionaloverage with bare-metal stents (BMS) and sirolimus- pluting polymer-coated stents on which the power calculation
as based (10), and secondly there was a clinical desire to gain
echanistic insight into the potential safety of the withdrawal
f clopidogrel at this relatively early time in nonpolymer
apamycin-eluting stents, as compared with the usually recom-
ended 1 year for polymer-coated rapamycin-eluting stents.
CT image acquisition. OCT was performed with the M2
ystem (LightLab Imaging Inc., Westford, Massachusetts) as
reviously described (11). Briefly, an over-the-wire proximal
cclusion balloon catheter (Helios, Goodman Inc., Nagoya,
apan) was deployed and the imaging catheter advanced
ImageWire, LightLab Imaging Inc.) with the light source
istal to the stent. The occlusion balloon was inflated to a
aximum of 0.7 atms for a maximum of 30 s with continual
lectrocardiographic monitoring while the coronary artery was
nfused with Ringer’s lactate at 0.5 to 1.0 ml/s using a power
njector (Mark V ProVis, Medrad, Inc., Indianola, Pennsylva-
ia). A motorized pullback at 1 mm/s was performed acquiring
ross-sectional images at 15.6 frames/s. Frames analyzed were
hose occurring at every 1 mm (15 frames). In addition, the 2
djacent frames both proximal and distal to the frame were also
ssessed to confirm tissue coverage or absence of tissue and
pposition. If the stent could not be visualized with a single
ullback (due to a long stent or patient intolerance), scanning
as prematurely terminated and the pull-back stopped with a
econd pull-back started from the site where it was interrupted.
natomical landmarks such as side branches, calcifications, or
tent overlap segments were used for longitudinal orientation.
CT analysis. OCT data analysis was performed offline
sing proprietary software (LightLab Imaging Inc.). Anal-
sis of angiographic images, quantitative coronary angiog-
aphy (Medis, Leiden, the Netherlands), and OCT was
erformed by experienced investigators (P.B. and P.M.).
egarding blinding, the very different presentation of the 2
tent types (including, in particular, the hub of the devices
nd the angiographic appearances of the markers) made it
mpractical to blind the operators; however, for the angio-
raphic and OCT analysis, investigators were blinded to the
andomization arm. The analyst was blinded to all clinical
nd procedural variables and thus, did not have any knowl-
dge of stent sizes or stent type. When a strut was felt to be
malapposed,’ the distance from the strut to lumen surface
as recorded. Only after completion of the analysis was the
tent type used to then confirm the presence or absence of
alapposition by incorporating the actual strut thickness for
he 2 stents used. This is required as OCT is unable to
enetrate through metal and thus can only visualize the
uminal aspect of the stent strut.
A blooming effect can result from hyperdense signals arising
rom metal struts. It is an optical property of the inferometer
nd, hence, an inevitable part of OCT. We did observe this,
nd, on the few occasions it was apparent, a frame immediately
roximal or distal was selected without this effect. Although we
a
f
s
c
l
(
c
c
A
w
p
t
e
e
l
i
s
(
s
t
s
p
T
O
w
t
on, an
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 5 , 2 0 0 9 Moore et al.
MA Y 2 0 0 9 : 4 3 7 – 4 4 Randomized Trial of Rapamycin-Eluting Stents
439re aware of such an effect, this was not an issue observed in the
ew stent struts malapposed (12).
Neointimal thickness (m) on the luminal side of each
trut section was measured. Neointimal area (mm2) was
alculated by manually tracing and subtracting the stent and
uminal areas. Percentage neointimal area was calculated as:
[stent area  lumen area]/stent area)  100. Binary strut
overage (%) was calculated as: (number of strut sections
overed/total number of strut sections examined)  100.
pposition: strut sections in contact with the vessel wall
ere defined as apposed. Strut sections were malapposed if
rotruding into the lumen at a distance greater to the strut
hickness (154 m for the polymer-coated rapamycin-
luting stent and 90 m for the nonpolymer rapamycin-
luting stent). Protrusion was defined as projection of the
Figure 1. Schematic Diagram of Stent Strut Apposition, Coverage, Protrusi
Table 1. Baseline Clinical and Procedural Characteristics
Variable
Polymer-Coated
Rapamycin Stent
Nonpolymer
Rapamycin Stent
Number 12 12
Age (yrs) 61.6 62.3
Male sex, n (%) 11 (92) 10 (83)
Follow-up, days (SD) 91 (6.7) 91 (6.6)
Hypertension, n (%) 8 (67) 8 (67)
Diabetes mellitus, n (%) 4 (42) 3 (25)
Hypercholesterolemia, n (%) 10 (83) 11 (92)
Current or ex-smoker, n (%) 6 (50) 7 (58)
Acute coronary syndrome, n (%) 4 (33) 3 (25)Chronic stable angina, n (%) 6 (67) 9 (75)uminal surface of the strut section (whether covered or not)
nto the lumen, relative to the intima between the adjacent
trut sections. The protrusion ratio (%) was calculated as:
number of protruding strut sections/total number of strut
ections)  100. In the text, all parameters quoted are for
he group level analysis of total number of strut sections
tudied in each stent type cohort. The terms apposition,
rotrusion, and coverage are demonstrated in Figure 1.
hree-dimensional (3D) reconstruction. Representative
CT sections appearing to show protruding stent struts
ere subjected to 3D reconstruction for comparison with
he known stent geometry to support validation of OCT for
d Restenosis
Table 2. Procedural Characteristics and Angiographic Follow-Up
Variable
Polymer-Coated
Rapamycin Stent
Nonpolymer
Rapamycin Stent
Vessel treated LAD 9/Cx 1/RCA 1 LAD 6/Cx 4/RCA 2
Stent diameter (mm) 2.88 (0.20) 2.88 (0.38)
Stent length (mm) 18.0 (3.0) 20.2 (2.9)
Post-dilation, n (%) 5 (41.7) 1 (8.3)
Maximal inﬂation pressure (atm) 17.0 (3.1) 16.7 (2.8)
Inﬂation duration (s) 18.9 (6.2) 15.4 (7.2)
1 stent, n (%) 8 (66.7) 6 (50.0)
2 stents, n (%) 3 (25.0) 6 (50.0)
3 stents, n (%) 1 (8.3) 0 (0)
Stent:artery ratio 1.14 (0.09) 1.06 (0.09)
90-day restenosis, n (%) 0 (0) 0 (0)
Late loss (mm) 0.06 (0.29) 0.16 (0.33)Cx circumflex artery; LAD left anterior descending coronary artery; RCA right coronary artery.
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440uantifying this characteristic. Intensity iso-contours delin-
ating the lumen-wall interface were extracted from the
CT data. Points on the extracted iso-contours were then
sed to reconstruct a triangulation of the lumen-wall inter-
ace (13). Image coloration gives a qualitative indication of
he local curvature of the surface and highlights particular
eatures of the lumen-wall interface.
thics and trial registration. The study was approved by the
rompton, Harefield, and National Heart and Lung Insti-
ute ethics committees, United Kingdom (06/Q0404/61).
ll patients enrolled gave written informed consent (Inter-
Figure 2. Neointimal Thickness by Stent Group and by Patient
Combined results of neointimal thickness by the randomized stent groups (ba
Table 3. OCT Follow-Up
Variable
Polymer-Coated Rapamycin Stent
Mean (SD)
Neointimal thickness (um) 72.7 (25.6)
Strut coverage (%) 88.3 (11.8)
Protruding struts (%) 26.5 (17.5)
Struts counted per frame (n) 8.2 (1.3)
Apposed and uncovered struts (%) 8.9 (12.4)
Malapposed struts (%) 2.2 (2.1)
Uncovered and malapposed struts (%) 1.7 (1.6)
Covered and malapposed struts (%) 0.4 (0.8)
Stent area (mm2) 8.8 (2.0)
Lumen area (mm2) 8.0 (2.0)
Neointimal area (mm2) 0.3 (0.2)
CI confidence interval; OCT optical coherence tomography; SD standard deviation.n  24 patients presented as median [interquartile range]).ational Randomized Controlled Trial Registration number
SRCTN42475919).
nd points and statistical methods. The primary end point
as binary stent strut coverage (%). Coprimary end points
ere neointimal thickness (m) and luminal strut protru-
ion (%). Secondary end points were malapposition and
tent, lumen, and neointimal areas.
The power calculation was based upon limited presented
onrandomized data available at the time suggesting a
ignificant difference in stent strut coverage between BMS
n  5) and polymer-coated rapamycin-eluting stents (n 
n  5,330 strut sections presented as mean [SD]) and by patient (histogram
Nonpolymer Rapamycin Stent
Mean (SD) Difference (95% CI) p Value
191.2 (86.7) 118.6 (64.4 to 172.7) 0.001
97.2 (6.1) 8.9 (0.9 to 16.8) 0.030
4.8 (8.6) 21.7 (33.34 to10.0) 0.001
8.4 (1.3) 0.2 (0.9 to 1.3) 0.700
2.4 (6.0) 6.6 (16.0 to 3.0) 0.170
1.2 (1.1) 0.9 (3.2 to 1.3) 0.380
0.4 (0.8) 1.3 (2.5 to0.1) 0.049
0.2 (0.4) 0.2 (0.8 to 0.3) 0.410
8.0 (1.9) 0.8 (2.5 to 0.8) 0.310
6.1 (1.7) 1.9 (3.5 to0.4) 0.020
1.2 (0.8) 0.9 (0.3 to 1.4) 0.002r chart
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4412) with 2-month OCT follow-up (10). In this study there
as a large (2-fold) difference in strut coverage between
he 2 stent types, and we estimated that 12 patients in each
roup would be adequate to demonstrate a difference in
overage between the 2 stent types in our study based on the
remise that the nonpolymer rapamycin-eluting stent would
robably yield a coverage intermediate between that of a
MS and the polymer-coated rapamycin-eluting stent.
To account for the repeated measurements within each
atient, the values for each end point were derived for each
ndividual frame (n  623), and then the average of all that
atient’s frames was calculated to give a final summary value
or each patient. Comparisons between the polymer-coated
nd polymer-free rapamycin-eluting stent groups were
ade using t tests. For the main outcomes, the results are
resented as mean (SD) along with the mean difference and
he associated 95% confidence interval. A 2-sided p value of
0.05 was considered to be statistically significant. In order
or this trial to be considered as having a positive outcome,
he primary end point had to achieve a value of p  0.05.
ther p values are exploratory in nature. Analysis was
arried out using STATA 9.2 (StataCorp, College Station,
exas).
esults
atient characteristics and procedural details are summa-
ized in Tables 1 and 2. There were no significant compli-
Figure 3. Binary Strut Coverage by Stent Group and by Patient
Combined results of binary strut coverage by the randomized stent groups (ba
gram n  24 patients presented as median [interquartile range]).ations of stent implantation. At follow-up angiography and
CT analysis, chest pain or ST-segment elevation on
ontinuous electrocardiogram (ECG) recording mandated
alloon deflation, and in all cases this resulted in prompt
esolution of pain and return of the ECG to baseline. There
ere no incidences of ventricular fibrillation or visible
hrombus during the OCT. All study stents were patent at
ollow-up with no cases of angiographic restenosis (defined
s 50% diameter angiographic stenosis relative to the
roximal reference segment).
A total of 5,330 strut sections were analyzed (polymer-
oated rapamycin-eluting stent: 2,465; and nonpolymer
apamycin-eluting stent: 2,865). The OCT outcome data
re shown in Table 3, and summarized in Figures 2 through
at both group and patient levels. The primary end point of
inary stent strut coverage indicated significantly greater
inary coverage with the nonpolymer rapamycin-eluting
tent than the polymer-coated rapamycin-eluting stent.
A representative 3D reconstruction of a polymer-coated
apamycin-eluting stent with evidence of protruding struts
atched closely with the known strut geometry of the bare
n vitro stent and is compared with a nonprotruding,
onpolymer rapamycin-eluting stent (Fig. 5).
iscussion
hese data demonstrate that although the polymer-coated
apamycin-eluting stent shows reduced neointimal thick-
rt n  5,330 strut sections presented as mean [SD]) and by patient (histo-r cha
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442ess compared with the nonpolymer rapamycin-eluting
tent, this is associated with a significantly higher number of
ncovered and luminally protruding struts. Experimental
ata suggest these may be adverse features. Importantly,
ngiographic late loss is a parameter based focally upon the
oint of maximum neointimal hyperplasia, and therefore
elevant when considering flow limitation. In contrast, this
ethodology provides a more global picture of stent strut
eointimal growth, coverage, and protrusion, which is often
onuniform and is likely therefore to be more representative
hen considering potential predictors of thrombotic risk.
egarding the polymer coat as a system for drug delivery,
vidence suggests that this may be pro-inflammatory in its
wn right and may retard healing and therefore coverage
14). The etched porous surface of the nonpolymer
apamycin-eluting stent as a drug delivery system in contrast
as no potentially pro-inflammatory coating.
A number of OCT series have been reported (15–17);
owever, investigators are still working toward consensus
ith regard to which parameters are the most patho-
hysiologically relevant, what precise methodology should
e used to analyze the images, and, as yet, have reported no
andomized trial data.
Observational studies using OCT have examined neoin-
imal thickness in the polymer-coated rapamycin-eluting
tent. Tatsuya et al. (10) undertook OCT examination at 3
onths and 2 years after polymer-coated rapamycin-eluting
Figure 4. Binary Luminal Strut Protrusion by Stent Group and by Patient
Combined results of binary luminal strut protrusion by the randomized stent g
(histogram n  24 patients presented as median [interquartile range]).tent implantation in 21 patients. The neointimal thickness at 2 years was greater than that at 3 months (71  93 m
s. 29  41 m, respectively; p  0.001). The frequency of
ncovered struts was lower in the 2-year group compared
ith that in the 3-month group (5% vs. 15%, respectively;
 0.001). However, the prevalence of patients with
ncovered struts did not differ between the 3-month and the
-year group (95% vs. 81%, respectively). Matsumoto et al.
17) examined 57 polymer-coated rapamycin-eluting stents
n 34 patients at 6 months after implantation and found the
edian neointimal thickness to be 52.5 m with 89% of
truts covered and 11% exposed. This compares with our
ndings at 3 months post-implantation, with a mean
eointimal thickness of 77 m and 89% of struts covered.
eointimal thickness. In the present study, the neointimal
hickness seen with the nonpolymer rapamycin-eluting stent
as significantly greater than with the polymer-coated
apamycin-eluting stent. Dose-ranging studies, when com-
ared with a BMS, have indicated significant angiographic
ntirestenotic efficacy for the nonpolymer rapamycin-
luting stent (18) although it has not been formally com-
ared with the polymer-coated rapamycin-eluting stent in a
linical trial. In the randomized ISAR-Test study, the
onpolymer rapamycin-eluting stent, however, was seen to
e noninferior to a polymer-coated paclitaxel-eluting stent
Taxus, Boston Scientific Inc., Natick, Massachusetts) (mean
ifference in angiographic late loss between the groups was
.002 mm, p  0.02), with no significant differences between
(bar chart n  5,330 strut sections presented as mean [SD]) and by patientroupsngiographic restenosis rates or target vessel revascularization
(
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44319). Furthermore, a recently published registry series of
atients treated with more than 200 nonpolymer rapamycin
tents and the paclitaxel stent indicated no difference in major
dverse cardiac event rates at 6 months (20).
trut protrusion. Although the concept of stent strut pro-
rusion and flow disturbance as a potential contributor to
tent thrombosis is not widely recognized, the protrusion of
foreign body into the coronary lumen will disturb flow at
he blood-intima interface, potentially inducing complex
ow patterns, which may be thrombogenic in their own
ight. We suggest that the stent strut protrusion ratio may
otentially be an important parameter when considering the
afety of intracoronary stents.
Regarding the 3D reconstruction, this was an exploratory
echnique that was applied to some representative OCT 2D
mages and is being further developed, but was not used
uantitatively in this study.
tudy limitations. Stent strut coverage is not a clinical
utcome, but an important potential surrogate for throm-
Figure 5. Representative OCT Image and 3D Reconstruction for Different S
Representative 3-dimensional optical coherence tomography (OCT) image of stent
nonpolymer rapamycin-eluting stent (B) with paired 3-dimensional (3D) reconstruosis and, therefore, stent safety. The presence or absence of heointimal coverage is clearly as defined by the resolution of
CT and struts reported as bare could have had a thin
overing of tissue (10 m), though at this level the
iological protection of the coverage has been debated (21).
he trial was small in terms of patient numbers; however,
ore than 5,000 strut sections were analyzed with, on
verage, more that 150 per patient driving the statistical
ower. From a statistical standpoint, there were some
nequal variances; however, the t test remains robust when
ariances are not equal, and, furthermore, reanalyzing all
utcomes in Table 3 using the Mann-Whitney U test,
hich makes no distributional assumptions, gave extremely
imilar results in all cases. OCT was performed at a single,
elatively early time point. This was considered appropriate
n the light of the drive to develop drug-eluting stents in
hich dual antiplatelet therapy can potentially be stopped
elatively early to reduce bleeding risk, allow noncardiac
urgery, and reduce cost. Neointimal heterogeneity of opti-
al signal in different stent types has been described;
ypes
sections of an uncovered polymer rapamycin-eluting stent (A) and a covered
and reference photograph of a polymer-coated rapamycin-eluting stent.tent T
strutowever, neointimal compositional analysis was beyond the
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444cope of this study, which focused upon anatomical cover-
ge. Finally, OCT was not performed immediately after
tent deployment. Although this may have provided some
seful comparative information, it was judged that at this
oint in the evolution of the technique 2 OCT procedures
ere excessive from an ethical standpoint.
onclusions
his trial demonstrated that the polymer-coated rapamycin-
luting stent exhibited low neointimal thickness; however, this
as at the expense of10% of the struts being uncovered and
25% protruding into the lumen at 90 days by OCT criteria.
he nonpolymer rapamycin-eluting stent in contrast exhibited
reater neointimal thickness (with no angiographic or clinical
estenosis) with3% of struts uncovered and5% protruding.
hese findings have to be interpreted in the context of reduced
eointimal thickness being the very mechanism by which the
fficacy of polymer-coated rapamycin-eluting stents is
chieved, with a proven reduction in subsequent target vessel
evascularization. Nevertheless, uncovered and protruding
truts may be surrogates for thrombotic risk with the former
ndicating delayed healing, exposing the stent strut to the blood
nd the latter resulting in flow disturbance.
These findings challenge the paradigm that less in-stent
estenosis is better within a coronary stent, and we hypothesize
hat at least enough neointima to cover the stent struts and
revent protrusion may be important for safety. In addition, it
aises the possibility of earlier clopidogrel withdrawal in pa-
ients treated with nonpolymer rapamycin-eluting stents than
ith polymer-coated rapamycin-eluting stents. Proving these
oncepts will need clinical outcome trials; however, stent
overage and protrusion are logical parameters that can be
mployed in small scale trials to investigate the potential safety
f new and existing coronary stent technologies.
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